|
Charcot-Marie-Tooth Disease, Type Ia (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
A recent report (Neurology 2018;90:e518-3524) showed elevation of neurofilament light (NfL) in plasma of CMT1A disease patients, which correlated with disease severity.
|
31833243 |
2020 |
|
Central Nervous System Infection
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We aimed to determine if switching from TDF to TAF increases the risk of neuronal injury, by quantifying plasma levels of neurofilament light protein (NfL), a sensitive marker of neuronal injury in HIV CNS infection.
|
31826005 |
2019 |
|
Late-Infantile Neuronal Ceroid Lipfuscinosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Before treatment in 21 human subjects with CLN2 disease (age range: 1.72-6.85 years), neurofilament light levels were 48-fold higher (P < 0.001) than in 7 pediatric controls (age range: 8-11 years).
|
31814335 |
2019 |
|
CEROID LIPOFUSCINOSIS, NEURONAL, 2
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Before treatment in 21 human subjects with CLN2 disease (age range: 1.72-6.85 years), neurofilament light levels were 48-fold higher (P < 0.001) than in 7 pediatric controls (age range: 8-11 years).
|
31814335 |
2019 |
|
Subarachnoid Hemorrhage
|
0.020 |
Biomarker
|
disease |
BEFREE |
Plasma Neurofilament Light Chain Is Associated with Poor Functional Outcome and Mortality Rate After Spontaneous Subarachnoid Hemorrhage.
|
31808039 |
2019 |
|
Delirium
|
0.020 |
Biomarker
|
disease |
BEFREE |
Neurofilament light rose more sharply in participants with delirium compared to non-sufferers [mean difference (95% CI) = 0.251 (0.136, 0.367) log10 (pg/ml), P < 0.001].
|
31802104 |
2020 |
|
Postoperative delirium
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Postoperative delirium is associated with increased plasma neurofilament light.
|
31802104 |
2020 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate whether baseline concentrations of plasma total tau (t-tau) and neurofilament light (NfL) chain proteins are associated with annual percent change (APC) of the basal forebrain cholinergic system (BFCS) in cognitively intact older adults at risk for Alzheimer disease (AD).
|
31801830 |
2020 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results from recent clinical studies suggest that cerebrospinal fluid (CSF) biomarkers that are indicative of Alzheimer's disease (AD) can be replicated in blood, e.g. amyloid-beta peptides (Aβ<sub>42</sub> and Aβ<sub>40</sub>) and neurofilament light chain (NFL).
|
31779670 |
2019 |
|
Glaucoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The NFLP_MD had better diagnostic accuracy than both VF_MD and overall NFL thickness and may be useful for early glaucoma diagnosis.
|
31770516 |
2020 |
|
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Neurofilament Light Chain in Cerebrospinal Fluid and Blood as a Biomarker for Neurodegenerative Diseases: A Systematic Review and Meta-Analysis.
|
31744001 |
2019 |
|
Amyotrophic Lateral Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To determine the diagnostic and prognostic significance of neurofilament light chain (NfL), TAR DNA-binding protein 43 (TDP-43), and total tau (t-tau) in cerebrospinal fluid (CSF) and plasma of patients with amyotrophic lateral sclerosis (ALS) and to investigate whether the combined use of those biomarker candidates can improve their diagnostic performance.
|
31742901 |
2019 |
|
Charcot-Marie-Tooth Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
In summary, we developed a human tridimensional in vitro system that models length-dependent axonopathies, recapitulates key pathophysiologic features of CMT2E, and should facilitate the identification of new therapeutic compounds for CMT.
|
31715019 |
2019 |
|
Amyloidosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
CSF neurogranin, YKL-40, and neurofilament light increased after the point of Aβ PET positivity.
|
31709776 |
2019 |
|
Amyotrophic Lateral Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Noviplex dried plasma spot (Np-DPS) and dried blood spot (DBS) on filter paper can be a remote, quick and inexpensive way of obtaining blood microsamples for the measurement of a large number of analytes in non-hospitalized, public health settings (5).We have used commercially-available and highly sensitive immunodetection assays (6) to test neurofilament light chain (Nf-L) expression in elute from DBS and from Np-DPS and compared these to standard Nf-L plasma measurement of healthy controls and patients with amyotrophic lateral sclerosis (ALS).We show that DBS and Np-DP cards can be used for remote blood collection and measurement of Nf-L. Nf-L measurement using elute from Noviplex DPS cards is equivalent to that obtained in plasma from the same blood samples, while levels of the same analyte in DBS elute are different, but provide discrimination between controls and ALS patients.
|
31702471 |
2019 |
|
Frontotemporal dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study.
|
31701893 |
2019 |
|
Pick Disease of the Brain
|
0.090 |
Biomarker
|
disease |
BEFREE |
Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study.
|
31701893 |
2019 |
|
Mild cognitive disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasma NFL shows particular promise as an accessible biomarker with relevance to cognition in MCI.
|
31700989 |
2019 |
|
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Neurofilament light chain (NfL) was recently proposed as a serum biomarker for many neurodegenerative disorders.
|
31684998 |
2019 |
|
Machado-Joseph Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3.
|
31684998 |
2019 |
|
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Neurofilament light chain (NfL) is a promising marker of disease activity/treatment response in multiple sclerosis (MS), although its predictive value for long-term clinical outcomes remains unclear.
|
31680621 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals.
|
31673598 |
2019 |
|
Brain Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Neurofilament light chain (NfL) is a promising blood biomarker to detect neurodegeneration in Alzheimer's disease (AD) and other brain disorders.
|
31673598 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Only NF-L differed between all stages within the AD continuum.
|
31668967 |
2020 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.070 |
Biomarker
|
disease |
BEFREE |
Circulating levels of neurofilament light chain (NfL) are a biomarker of disease activity in RRMS.
|
31657006 |
2020 |